Overview

A Research Study to See How Well CagriSema Helps People Losing Weight in People Who Have a Body Weight Above the Healthy Range and Type 2 Diabetes

Status:
Not yet recruiting
Trial end date:
2024-10-28
Target enrollment:
Participant gender:
Summary
This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. The study will last for about 1½ years. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.
Phase:
Phase 3
Details
Lead Sponsor:
Novo Nordisk A/S